IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.984 CHF | +0.76% |
|
-12.91% | -6.15% |
| Jun. 03 | Idorsia Ltd. Announces New Data with Daridorexant to Be Presented at Sleep 2024 | CI |
| May. 21 | Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 114M 127M | Sales 2025 * | 210M 235M | Capitalization | 354M 396M |
|---|---|---|---|---|---|
| Net income 2024 * | -397M -444M | Net income 2025 * | -355M -397M | EV / Sales 2024 * | 11.8 x |
| Net Debt 2024 * | 993M 1.11B | Net Debt 2025 * | 1.09B 1.22B | EV / Sales 2025 * | 6.88 x |
| P/E ratio 2024 * |
-1.4
x | P/E ratio 2025 * |
-1.8
x | Employees | 650 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +6.15% | ||
| 1 week | -10.36% | ||
| Current month | -21.28% | ||
| 1 month | -9.41% | ||
| 3 months | +16.89% | ||
| 6 months | -4.22% | ||
| Current year | -3.41% |
1 week
1.96
2.27
1 month
1.962.70
Current year
1.293.70
1 year
1.298.47
3 years
1.2926.62
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 775 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 1.984 | +0.76% | 384 745 |
| 24-06-13 | 1.969 | -2.72% | 313,221 |
| 24-06-12 | 2.024 | -6.04% | 597,314 |
| 24-06-11 | 2.154 | -1.19% | 271,791 |
| 24-06-10 | 2.18 | -4.30% | 242,356 |
Delayed Quote Swiss Exchange, June 14, 2024 at 03:25 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-07-25
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.969
CHF
Average target price
1.692
CHF
Spread / Average Target
-14.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.41% | 396M | |
| +17.73% | 124B | |
| +16.88% | 111B | |
| -9.04% | 23.17B | |
| +4.31% | 22.94B | |
| -38.15% | 17.42B | |
| -7.75% | 17.42B | |
| -15.64% | 16.9B | |
| +3.42% | 13.71B | |
| +29.63% | 11.82B |
- Stock Market
- Equities
- IDIA Stock
